Corporate News: Zhejiang Hisun Pharmaceutical Co., Ltd.

Zhejiang Hisun Pharmaceutical Co., Ltd. (ticker: 600267.SS) closed its trading session unchanged at CNY 13.72 on Thursday, 22 October 2026, as Central European markets recorded a flat 0 % movement during the 24‑hour period ending at 09:50 PM. The firm’s shares are currently trading within a range that reflects the broader stability observed across the Shanghai Stock Exchange.

Trading Metrics

  • Shares Outstanding: 1.10 billion
  • Market Capitalisation: CNY 15.4 billion
  • Volume in Last 24 Hours: Approximately CNY 2.0 billion worth of shares were exchanged.
  • Year‑to‑Date Performance: Since the end of September, the stock has risen 18.62 %.
  • Technical Indicators: The 200‑day simple moving average sits at CNY 11.47, while the 52‑week high of CNY 15.00 was reached on 14 August 2026, and the low of CNY 9.35 was recorded on 22 June 2026.

Recent Corporate Developments

The company’s third‑quarter earnings preview has generated a mixed yet cautiously optimistic outlook among investors. Analysts note that revenue and net profit are projected to increase, largely driven by expanded production of key active ingredients and the growing sales of novel therapeutic products. Despite a modest decline in overall sales—attributable to the divestiture of certain business units—the adjusted year‑on‑year figures indicate a steady improvement.

A robust pipeline of new drugs, coupled with an expanding presence in overseas markets, has been highlighted by a series of international licensing agreements and strategic collaborations. These developments are expected to reinforce the firm’s competitive position in the domestic pharmaceutical sector, which is experiencing a broader resurgence.

Market Context

In the past 24 hours, several related stocks have shown varied performance:

  • Shenzhen Special Econ Zone (000029.SZ): flat at 0 %, trading at CNY 19.86; market capitalisation of CNY 18.4 billion.
  • State Grid Information & C (600131.SS): flat at 0 %, trading at CNY 14.80; market capitalisation of CNY 18.4 billion; price‑to‑earnings ratio of 28.9.
  • Shanghai Haoyuan Chemexpre (688131.SS): flat at 0 %, trading at CNY 83.20; market capitalisation of CNY 18.4 billion; price‑to‑earnings ratio of 74.01.
  • Shanxi Securities (002500.SZ): flat at 0 %, trading at CNY 4.99; market capitalisation of CNY 18.4 billion; price‑to‑earnings ratio of 18.25.
  • Dekon Food & Agriculture-h (2419.HK): up 4.12 %, trading at HKD 57.30; market capitalisation of HKD 21.6 billion.

These movements illustrate a broader trend of market stability, with technology and media shares gaining modestly, while battery and automotive sectors experienced slight declines. The Chinese authorities’ continued emphasis on the “AI+” agenda and support for domestic data‑center growth underscores the evolving landscape in which Zhejiang Hisun Pharmaceutical operates.

Company Profile

Zhejiang Hisun Pharmaceutical Co., Ltd. was founded in 2000 and went public on 5 July 2000. Headquartered in Taizhou, China, the company is listed on the Shanghai Stock Exchange. Its product portfolio spans anticancer drugs, cardiovascular medicines, anti‑parasitics, and anti‑infective agents, complemented by related pharmaceutical solution services. Further information can be found on the company’s website: www.hisunpharm.com .

This article synthesises the latest market data, corporate developments, and contextual market trends to provide investors with a comprehensive overview of Zhejiang Hisun Pharmaceutical’s current position within China’s pharmaceutical sector.